Cargando…

Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2

BACKGROUND: Upadacitinib is a Janus kinase inhibitor under evaluation for the treatment of psoriatic arthritis (PsA). We evaluated upadacitinib in patients with PsA and prior inadequate response or intolerance to at least one biologic disease-modifying antirheumatic drug (DMARD). METHODS: In this 24...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mease, Philip J, Lertratanakul, Apinya, Anderson, Jaclyn K, Papp, Kim, Van den Bosch, Filip, Tsuji, Shigeyoshi, Dokoupilova, Eva, Keiserman, Mauro, Wang, Xin, Zhong, Sheng, McCaskill, Reva M, Zueger, Patrick, Pangan, Aileen L, Tillett, William
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Psoriatic Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892371/ https://www.ncbi.nlm.nih.gov/pubmed/33272960 http://dx.doi.org/10.1136/annrheumdis-2020-218870

Ejemplares similares

Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study
por: Mease, Philip J., et al.
Publicado: (2021)

Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
por: McInnes, Iain B, et al.
Publicado: (2021)

Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA)
por: Mease, Philip J, et al.
Publicado: (2018)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
por: Helliwell, Philip S, et al.
Publicado: (2022)

4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis
por: van der Heijde, Désirée, et al.
Publicado: (2018)

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial
por: Kristensen, Lars Erik, et al.
Publicado: (2022)

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1
por: Coates, Laura C, et al.
Publicado: (2017)

Real-world burden of comorbidities in US patients with psoriatic arthritis
por: Shah, Kamal, et al.
Publicado: (2017)

Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsA
por: Richette, Pascal, et al.
Publicado: (2023)

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial
por: Mease, Philip J, et al.
Publicado: (2017)

Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J, et al.
Publicado: (2018)

Impact of psoriatic arthritis and comorbidities on ustekinumab outcomes in psoriasis: a retrospective, observational BADBIR cohort study
por: Tillett, William, et al.
Publicado: (2023)

Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set
por: Kalyoncu, Umut, et al.
Publicado: (2016)

Patient’s experience of psoriatic arthritis: a conceptual model based on qualitative interviews
por: Ogdie, Alexis, et al.
Publicado: (2020)

Measurement properties of the minimal disease activity criteria for psoriatic arthritis
por: Coates, Laura C, et al.
Publicado: (2019)

Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials
por: Mease, Philip J, et al.
Publicado: (2021)

Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis
por: Huynh, D H, et al.
Publicado: (2017)

Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry
por: Mease, Philip J, et al.
Publicado: (2015)

Treat-to-target in PsA: methods and necessity
por: Dures, Emma, et al.
Publicado: (2020)

Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24-Week Patient-Reported Outcome Results of a Phase III, Multicenter Study
por: Gladman, D, et al.
Publicado: (2014)

Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials
por: Mease, Philip, et al.
Publicado: (2019)

Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study
por: Coates, Laura C, et al.
Publicado: (2023)

Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial
por: Baraliakos, Xenofon, et al.
Publicado: (2022)

Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial
por: Mease, Philip J., et al.
Publicado: (2019)

Treatment‐to‐Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations
por: Mease, Philip J., et al.
Publicado: (2020)

Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
por: Mease, Philip J, et al.
Publicado: (2022)

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
por: Coates, Laura C, et al.
Publicado: (2022)

Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combination
por: Strand, Vibeke, et al.
Publicado: (2021)

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial
por: Östör, Andrew, et al.
Publicado: (2022)

Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib
por: de Vlam, Kurt, et al.
Publicado: (2021)

Transition phase towards psoriatic arthritis: clinical and ultrasonographic characterisation of psoriatic arthralgia
por: Zabotti, Alen, et al.
Publicado: (2019)

Understanding the association between skin involvement and joint activity in patients with psoriatic arthritis: experience from the Corrona Registry
por: Mease, Philip J, et al.
Publicado: (2019)

Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial
por: McInnes, Iain B, et al.
Publicado: (2019)

Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis
por: van der Heijde, Désirée, et al.
Publicado: (2016)

Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studies
por: Gladman, Dafna D, et al.
Publicado: (2018)

Psoriatic arthritis: an evolving matter
por: Wendling, Daniel
Publicado: (2015)

Construct validity and responsiveness of feasible composite disease activity measures for use in daily clinical practice in patients with psoriatic arthritis
por: Kasiem, Fazira R., et al.
Publicado: (2023)

Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry
por: Mease, Philip J, et al.
Publicado: (2019)

Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure
por: Mease, P, et al.
Publicado: (2015)

Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial
por: Mease, Philip J, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5op8h8ev4ihn4mhuode89fqumr